At the 2016 Association for Research in Vision and Ophthalmology (ARVO) meeting in Seattle, about 100 uveitis and uveitis-related papers and posters were presented by researchers from around the world. The presentations covered a wide range of research initiatives that are underway to treat–or at least understand how to address–uveitis. Here are five intriguing abstracts of research that were presented at the meeting.
Uveitis presents particular problems for ophthalmologists. Inflammation inside the eye can occur from so many causes that the diagnosis often requires painstaking, time-consuming investigation. As researchers have learned more about the disease, the possible etiologies and treatments have multiplied.
Glaucoma is a common complication of uveitis, occurring in about 20% of affected eyes and arising through several different mechanisms.
Here are seven common mistakes clinicians make in evaluating and managing elevated IOP in eyes with uveitis.
Intravenous administration of the anti-interleukin-6 (IL-6) agent tocilizumab (Actemra, Genentech) is well-tolerated in patients with non-infectious uveitis involving the posterior segment and showing promising efficacy, according to interim outcomes reported by Quan Dong Nguyen, MD.